Labiotech provides listing of 2026 biotech conferences and events purely as a service for readers. We are not responsible for any errors in dates or omissions.
A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback